Literature DB >> 18266647

Liver eosinophilic infiltrate is a significant finding in patients with chronic hepatitis C.

G Tarantino1, D Cabibi, C Cammà, N Alessi, M Donatelli, S Petta, A Craxì, V Di Marco.   

Abstract

Eosinophilic infiltrate of liver tissue is described in primary cholestatic diseases, hepatic allograft rejection and drug-induced liver injury, but its significance and its implications in chronic hepatitis C are unknown. The aim of this study was to investigate the clinical significance of eosinophilic liver infiltrate in patients with chronic hepatitis C. We retrospectively evaluated 147 patients with chronic hepatitis C. The presence of eosinophilic infiltrate was investigated in liver biopsies, and a numeric count of eosinophilic leucocytes in every portal tract was assessed. An eosinophilic infiltrate of liver tissue (> or =3 cells evaluated in the portal / periportal spaces) was observed in 46 patients (31%), and patients who consumed drugs had an odds ratio (OR) of 4.02 (95% CI: 1.62-9.96) to have an eosinophilic infiltrate in liver biopsy. By logistic regression analysis, the presence of steatosis was independently associated with eosinophilic infiltrate (OR 5.86; 95% CI: 2.46-13.96) and homeostasis model assessment-score (OR 1.18; 95% CI: 1.00-1.39). Logistic regression analysis also showed that fibrosis staging > or = 2 by Scheuer score was associated with grading >1 by Scheuer score (OR 6.82; 95% CI 2.46-18.80) and eosinophilic infiltrate (OR 4.00; 95% CI 1.23-12.91). In conclusion, we observed that the eosinophilic infiltrate of liver tissue was significantly more frequent in patients who assumed drugs, and found a significant association between eosinophilic infiltrate, liver steatosis and liver fibrosis. These preliminary data could lead to a constant assumption of drugs as a co-factor of eosinophils-mediated liver injury in chronic hepatitis C.

Entities:  

Mesh:

Year:  2008        PMID: 18266647     DOI: 10.1111/j.1365-2893.2008.00976.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  11 in total

1.  Eosinophils mediate the pathogenesis of halothane-induced liver injury in mice.

Authors:  William R Proctor; Mala Chakraborty; Lynette S Chea; Jeffrey C Morrison; Julia D Berkson; Kenrick Semple; Mohammed Bourdi; Lance R Pohl
Journal:  Hepatology       Date:  2013-03-15       Impact factor: 17.425

2.  Eosinophils attenuate hepatic ischemia-reperfusion injury in mice through ST2-dependent IL-13 production.

Authors:  Yaochun Wang; Yang Yang; Meng Wang; Shuhong Wang; Jong-Min Jeong; Long Xu; Yankai Wen; Christoph Emontzpohl; Constance Lynn Atkins; Kevin Duong; Nicolas F Moreno; Xiaoyi Yuan; David R Hall; Wasim Dar; Dechun Feng; Bin Gao; Yong Xu; Zoltan Czigany; Sean P Colgan; J Steve Bynon; Shizuo Akira; Jared M Brown; Holger K Eltzschig; Elizabeth A Jacobsen; Cynthia Ju
Journal:  Sci Transl Med       Date:  2021-02-03       Impact factor: 17.956

3.  Hepatic recruitment of eosinophils and their protective function during acute liver injury.

Authors:  Long Xu; Yang Yang; Yankai Wen; Jong-Min Jeong; Christoph Emontzpohl; Constance L Atkins; Zhaoli Sun; Kyle L Poulsen; David R Hall; J Steve Bynon; Bin Gao; William M Lee; Jody Rule; Elizabeth A Jacobsen; Hua Wang; Cynthia Ju
Journal:  J Hepatol       Date:  2022-03-05       Impact factor: 30.083

4.  Nrf2 protects against As(III)-induced damage in mouse liver and bladder.

Authors:  Tao Jiang; Zheping Huang; Jefferson Y Chan; Donna D Zhang
Journal:  Toxicol Appl Pharmacol       Date:  2009-06-16       Impact factor: 4.219

5.  Thymic stromal lymphopoietin and interleukin-4 mediate the pathogenesis of halothane-induced liver injury in mice.

Authors:  William R Proctor; Mala Chakraborty; Aaron M Fullerton; Midhun C Korrapati; Pauline M Ryan; Kenrick Semple; Jeffrey C Morrison; Julia D Berkson; Lynette S Chea; Qian Yang; Albert P Li; Rosanne Spolski; Erin E West; Yrina Rochman; Warren J Leonard; Mohammed Bourdi; Lance R Pohl
Journal:  Hepatology       Date:  2014-05-20       Impact factor: 17.425

Review 6.  Innate immune cells in liver inflammation.

Authors:  Evaggelia Liaskou; Daisy V Wilson; Ye H Oo
Journal:  Mediators Inflamm       Date:  2012-08-09       Impact factor: 4.711

7.  Daclatasvir and Sofosbuvir Therapy Enhance Monocyte Phenotypic Changes in Naive Chronic Hepatitis C Patients: A Prospective Cohort Study.

Authors:  Hanan M Fayed; Ali A Ghweil; Mona M AbdelMeguid
Journal:  Interdiscip Perspect Infect Dis       Date:  2019-02-03

Review 8.  Pyroptosis in Liver Disease: New Insights into Disease Mechanisms.

Authors:  Jiali Wu; Su Lin; Bo Wan; Bharat Velani; Yueyong Zhu
Journal:  Aging Dis       Date:  2019-10-01       Impact factor: 6.745

Review 9.  Differential Location and Distribution of Hepatic Immune Cells.

Authors:  Maria Alice Freitas-Lopes; Kassiana Mafra; Bruna A David; Raquel Carvalho-Gontijo; Gustavo B Menezes
Journal:  Cells       Date:  2017-12-07       Impact factor: 6.600

Review 10.  Immune cells in liver regeneration.

Authors:  Na Li; Jinlian Hua
Journal:  Oncotarget       Date:  2017-01-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.